Exsilio Therapeutics

Exsilio Therapeutics is a biotechnology company developing genomic medicines for various diseases. Their platform uses naturally occurring genetic elements delivered via mRNA and lipid nanoparticles to precisely insert genes into the human genome. This approach aims for durable and potentially curative effects for genetic diseases, cancer, and autoimmune conditions.

Funding Round: Series A

Funding Amount: $82M

Date: 25-Jun-2024

Investors: Novartis Venture Fund, Delos Capital, OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, Deep Insight

Markets: Biotechnology, Genomics, mRNA Therapeutics

HQ: Boston, Massachusetts, United States

Founded: 2022

Website: https://exsiliotx.com/

LinkedIn: https://www.linkedin.com/company/exsiliotx

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/exsilio-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/607040-47